Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $215M
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | Alta Partn... | altapartne... |
| - | RA Capital... | racap.com |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 20.06.2014 | IPO | $96M | - |
| 17.04.2014 | - | $20M | - |
| 04.12.2013 | Series E | $45M | - |
| 04.12.2012 | Series D | $21M | - |
| 07.07.2011 | Series C | $33M | - |
Mentions in press and media 24
| Date | Title | Description |
| 13.06.2019 | Zafgen presents Phase II data from Type 2 diabetes drug currently on FDA hold | The drug is a MetAP2 inhibitor, which according to a poster from the study is part of a class that has previously improved glycemic control and body weight in human subjects, as well as improving various measures in mice. The analysis inclu... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has established a strong track record with its first three funds. In less than 10 years, Third Rock has invested in 40 companies, advancing 40 clinical... |
| 19.07.2016 | Beleaguered Zafgen crushed after FDA demands force it to dump lead drug | Stymied at the FDA with a lingering clinical hold on its lead obesity drug, Zafgen is dumping the therapy and retreating to a preclinical program in the pipeline. The biotech announced after the market closed on Tuesday ... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 02.04.2015 | ZappRX raises $5.6M Series A as pharma becomes more responsive to specialty drug support needs | ZappRx will also work with obesity-focused biopharma company Zafgen (NASDAQ: ZFGN), to support patients with Prader-Willi syndrome — a genetic condition affecting up to 30,000 people — and hypothalamic injury-associated obesity. Promoted Th... |
| 19.06.2014 | IPO for obesity drug developer Zafgen raises $96 million | Instead of suppressing hunger, Zafgen’s obesity drug beloranib, inhibits the enzyme methionine aminopeptidase 2 and makes the body produce less fat and burn off the excess as fuel. Because the effects of the drug don’t appear to impact the ... |
| 17.04.2014 | Zafgen Closes $20M Term Loan | Zafgen, Inc., a Cambridge, MA-based biopharmaceutical company, closed a $20m term loan. Oxford Finance and MidCap Financial provided the loan. The company intends to use the proceeds for working capital growth. Founded in 2005, Zafgen devel... |
| 04.12.2013 | Zafgen lands a $45M round for its obesity drug study | Zafgen CEO Tom Hughes told FierceBiotech last month that he was closing in on a new fundraising round for the biotech, which is developing a promising new therapy for obesity. And the money has arrived. Today, Cambridge, MA-based Zafgen sai... |
| 04.12.2013 | Zafgen Secures $45M in Series E Equity Financing | Zafgen, Inc., a Cambridge, MA-based biopharmaceutical company focused on severely obese patients, secured $45m in a Series E equity financing. Backers included new investors RA Capital Management, Brookside Capital, Venrock, Alta Partners, ... |
| 04.12.2013 | Zafgen Secures $45M in Series E | CAMBRIDGE, MA, Leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $45 million in a Series E equity financing. >> Click here for more funding data on ... |
Show more